Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

49.59 -0.28 (-0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,675,058
Open 50.00
Bid (Size) 49.59 (2)
Ask (Size) 50.98 (10)
Prev. Close 49.87
Today's Range 49.18 - 51.99
52wk Range 37.55 - 91.10
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Biotech Stock Down 62% to Buy and Hold
It's an excellent opportunity to buy shares of what could become a biotech giant on the dip. 
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
An investment in these players today could score a big win down the road. 
Via The Motley Fool

Performance

YTD
-24.93%
-24.93%
1 Month
-0.48%
-0.48%
3 Month
-18.13%
-18.13%
6 Month
-31.09%
-31.09%
1 Year
+4.09%
+4.09%

More News

Read More
Looking for Stock Bargains With Room to Run? Try This.
Via The Motley Fool
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
Via The Motley Fool
3 Monster Biotech Stocks to Buy Before 2025
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
Got the Market Sell-Off Blues? Do These 3 Things Right Now
Via The Motley Fool
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
Via Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in August 2024
Via InvestorPlace
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
Via The Motley Fool
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
Via The Motley Fool
10 Best Small and Mid-Cap Stocks to Consider Buying in August
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024
Via InvestorPlace
3 Small-Cap Stocks to Buy at a 52-Week Low
Via InvestorPlace
3 Gene Editing Stocks Shaping the Future of Medicine
Via InvestorPlace
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
3 Gene Editing Stocks That Could Grow Your Wealth
Via InvestorPlace
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Via InvestorPlace
Blue Chips, Small Caps Extending Their Breakout
Via Talk Markets
Topics Stocks
Exposures US Equities
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.